Indications & Usage
Directions: FOR TOPICAL USE ONLY.
Borago Lavender Lotion
FDA Label NDC 48951-2144
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Uriel Pharmacy Inc. for the product Borago Lavender (NDC 48951-2144). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding indications & usage, dosage & administration, otc - active ingredient, inactive ingredient, otc - purpose, otc - keep out of reach of children, warnings, otc - questions, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Dosage & Administration
Apply to skin as needed. Under age 2: Consult a doctor.
Otc - Active Ingredient
Active Ingredients: 100 gm contains: 20 gm Aesculus (Horse chestnut seed) 1X, 20 gm Borago (Borage) 1X,
12 gm Melilotus (Yellow sweet clover) 1X
Inactive Ingredient
Inactive Ingredients: Distilled water, Organic cane alcohol, Witch Hazel distillate, Magnesium aluminum silicate,
Lavender oil, Xanthan gum, Sorbic acid, Tea tree oil, Grapefruit seed extract
Otc - Purpose
Uses: Temporarily relieves symptoms of varicose veins and leg cramps.
Otc - Keep Out Of Reach Of Children
KEEP OUT OF REACH OF CHILDREN.
Warnings
Warnings: FOR EXTERNAL USE ONLY.
Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.
Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions, if conditions worsen or persist,
or accidental ingestion occurs. If pregnant or nursing, consult a doctor before use. Avoid contact with eyes.
SHAKE WELL BEFORE USE.
Otc - Questions
Questions? Call 866.642.2858
Made with care by Uriel, East Troy, WI 53120
shopuriel.com
* Please review the disclaimer below.
